Outcome of COVID-19 in patients with rheumatic diseases treated with immunosuppressive drugs
Mansoura Medical Journal · 01.01.2023 · 52 (2)
DOI: 10.58775/2735-3990.1391 ↗Kurz gefasst
Fachartikel in der Zeitschrift Mansoura Medical Journal, online erschienen am 01.01.2023. Verfasst von Ali Sobh und 9 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Rheumatologic disorders have been significantly impacted by the coronavirus disease 2019 (COVID-19) pandemic. The potential role of immunosuppressive drugs in the presentation, severity and even management of COVID-19 is still questionable. The aim of this work was to study the effect of immunosuppressive drugs on outcome of COVID-19 infection in patients with rheumatic diseases. 109 rheumatic patients (37 pediatrics and 72 adults) taking immunosuppressive treatment with confirmed COVID-19 infection were included in this study. Clinical, laboratory, radiological findings and outcome of these patients were retrospectively retrieved from hospital medical records.
Results
The majority of adult cases were rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), while juvenile idiopathic arthritis (JIA) represented the majority of pediatric cases. There were 13 deaths (18.1%) among adults. While, no recorded deaths among the pediatrics. There was significant correlation between the use of steroids, biologics and radiological findings among adults. Also, there was significant correlation between the need for oxygenation with the use of mycophenolate mofetil (MMF) and steroids.
Conclusion
The impact of the use of immunosuppressive therapies during the COVID- 19 pandemic is variable depending on the type of drug and associated comorbidities. The decision whether to use these drugs or not must be tailored for each patient.
Zitieren
APA
Sobh, A., Elnagdy, N. H., Elegezy, M., Mofreh, M., Tohlob, M., Eita, A. M., Rizk, R., Eliwa, O., Elnagdy, M. H., & Abdulgalil, A. E. (2023). Outcome of COVID-19 in patients with rheumatic diseases treated with immunosuppressive drugs. Mansoura Medical Journal, 52(2). https://doi.org/10.58775/2735-3990.1391
Vancouver
Sobh A, Elnagdy NH, Elegezy M, Mofreh M, Tohlob M, Eita AM, et al. Outcome of COVID-19 in patients with rheumatic diseases treated with immunosuppressive drugs. Mansoura Medical Journal. 2023;52(2). doi:10.58775/2735-3990.1391
BibTeX
@article{Sobh2023,
author = {Sobh, Ali and Elnagdy, Noha Hazem and Elegezy, Mohamed and Mofreh, Mohamed and Tohlob, Mohamed and Eita, Ahmad M. and Rizk, Ragheed and Eliwa, Ola and Elnagdy, Marwa H. and Abdulgalil, Ahmed Elsaeed},
title = {Outcome of COVID-19 in patients with rheumatic diseases treated with immunosuppressive drugs},
journal = {Mansoura Medical Journal},
year = {2023},
volume = {52},
number = {2},
doi = {10.58775/2735-3990.1391}
}
EUVIMED